DNA Damage In Lymphocytes From Healthy Individuals And Respiratory Disease Patients, Treated Ex Vivo/in Vitro With Aspirin And Ibuprofen Nanoparticles Compared To Their Bulk Forms | 17894
Epidemiology: Open Access
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
on-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzyme activity, a significant mechanism of action of
NSAIDs. Inflammation is associated with increasing cancer incidence. Recent pre-clinical and clinical studies have
shown that NSAID treatment could cause an anti-tumour effect in cancers. Such studies are lengthy and expensive. The
present study, however, examined DNA damage in the Comet and micronucleus assays in peripheral blood lymphocytes
of patients with respiratory diseases and healthy individuals using the nanoparticle (NP) and bulk versions of the NSAIDs,
aspirin and ibuprofen. Lymphocytes are suitable surrogate cells for cancers and other disease states. DNA damage decreased
in lymphocytes from healthy individuals, asthma, COPD and lung cancer patient groups after treatment with aspirin nano
(ASP-N) and ibuprofen nano (IBU-N) compared to their bulk version in both assays. However, when ASP-N was compared to
untreated lymphocytes in all groups in the Comet assay, DNA damage significantly decreased in all groups, except the asthma
group. When IBU-N was compared to untreated lymphocytes, in healthy individuals and the lung cancer group, DNA damage
decreased, but increased in asthma and COPD groups. Similarly, micronuclei (MNi) increased after ASP-N and IBU-N in the
healthy individual and lung cancer groups, and decreased in asthma and COPD groups. Furthermore, lymphocytes responses
after IBU-N and ibuprofen bulk were investigated by the physiological patch-clamp technique. Patch-clamp recordings
demonstrated that IBU-N inhibited ion channel activity by 20%. This molecular epidemiology approach mirrors pre-clinical
and clinical findings, and provides further information using nanoparticles.
Diana Anderson currently holds the Established Chair of the Division of Biomedical Sciences at the University of Bradford, UK. She obtained her first degree in
the University of Wales and second degree in the Faculty of Medicine, University of Manchester. After tutoring at the University of Sydney, Australia, she became
a research worker in the Department of Cancer Studies at the University of Leeds and at the Paterson Laboratories, Christie Hospital, Manchester. She has
organized both National and International meetings and was/is a member of various national (e.g. MRC Advisory Board, Veterinary Products Committee) and was
of International committees, including the European Union Scientific Committee for Animal Nutrition (SCAN). She recently won a prize as an Enterprise Fellow.
She has hosted and participated in 56 meetings for WHO/IPCS. She is a consultant for many international organizations, such as the WHO, NATO, TWAS, UNIDO
and the OECD.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals